Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Elanco Animal Health Incorporated (ELAN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings By: Bronstein, Gewirtz & Grossman, LLC via Business Wire July 05, 2024 at 16:00 PM EDT Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated (“Elanco” or “the Company”) (NYSE: ELAN). Investors who purchased Elanco securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/ELAN. Investigation Details On June 27, 2024, Elanco issued a press release “announc[ing] updates to the expected U.S. Food and Drug Administration (FDA) approval timelines for Zenrelia and Credelio Quattro. The press release stated that Zenrelia is expected to receive FDA approval in the third quarter of 2024, leading to a potential commercial launch in the fourth quarter of 2024. The Company had previously set a launch timeline for the third quarter of 2024. The press release also stated that Credelio Quattro is expected to receive FDA approval in the fourth quarter of 2024, while the Company had previously set an approval timeline for the third quarter of 2024. Following this news, Elanco stock dropped $3.69 per share, or 20.53%, to close at $14.28 on June 27, 2024. What's Next? If you are aware of any facts relating to this investigation or purchased Elanco securities, you can assist this investigation by visiting the firm’s site: bgandg.com/ELAN. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660. There is No Cost to You We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful. Why Bronstein, Gewirtz & Grossman Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. Attorney advertising. Prior results do not guarantee similar outcomes. View source version on businesswire.com: https://www.businesswire.com/news/home/20240705199664/en/Contacts Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Nathan Miller 332-239-2660 | info@bgandg.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Elanco Animal Health Incorporated (ELAN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings By: Bronstein, Gewirtz & Grossman, LLC via Business Wire July 05, 2024 at 16:00 PM EDT Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated (“Elanco” or “the Company”) (NYSE: ELAN). Investors who purchased Elanco securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/ELAN. Investigation Details On June 27, 2024, Elanco issued a press release “announc[ing] updates to the expected U.S. Food and Drug Administration (FDA) approval timelines for Zenrelia and Credelio Quattro. The press release stated that Zenrelia is expected to receive FDA approval in the third quarter of 2024, leading to a potential commercial launch in the fourth quarter of 2024. The Company had previously set a launch timeline for the third quarter of 2024. The press release also stated that Credelio Quattro is expected to receive FDA approval in the fourth quarter of 2024, while the Company had previously set an approval timeline for the third quarter of 2024. Following this news, Elanco stock dropped $3.69 per share, or 20.53%, to close at $14.28 on June 27, 2024. What's Next? If you are aware of any facts relating to this investigation or purchased Elanco securities, you can assist this investigation by visiting the firm’s site: bgandg.com/ELAN. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660. There is No Cost to You We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful. Why Bronstein, Gewirtz & Grossman Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. Attorney advertising. Prior results do not guarantee similar outcomes. View source version on businesswire.com: https://www.businesswire.com/news/home/20240705199664/en/Contacts Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Nathan Miller 332-239-2660 | info@bgandg.com
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated (“Elanco” or “the Company”) (NYSE: ELAN). Investors who purchased Elanco securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/ELAN. Investigation Details On June 27, 2024, Elanco issued a press release “announc[ing] updates to the expected U.S. Food and Drug Administration (FDA) approval timelines for Zenrelia and Credelio Quattro. The press release stated that Zenrelia is expected to receive FDA approval in the third quarter of 2024, leading to a potential commercial launch in the fourth quarter of 2024. The Company had previously set a launch timeline for the third quarter of 2024. The press release also stated that Credelio Quattro is expected to receive FDA approval in the fourth quarter of 2024, while the Company had previously set an approval timeline for the third quarter of 2024. Following this news, Elanco stock dropped $3.69 per share, or 20.53%, to close at $14.28 on June 27, 2024. What's Next? If you are aware of any facts relating to this investigation or purchased Elanco securities, you can assist this investigation by visiting the firm’s site: bgandg.com/ELAN. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660. There is No Cost to You We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful. Why Bronstein, Gewirtz & Grossman Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. Attorney advertising. Prior results do not guarantee similar outcomes. View source version on businesswire.com: https://www.businesswire.com/news/home/20240705199664/en/
